CD33 and acute myeloid leukemia: A recent study showed that CD33-CAR-NK cells with CRISPR/Cas9-based disruption of the KLRC1 gene, which encodes the NKG2A inhibitory receptor, exhibited increased cytotoxicity against AML cells, both in vitro and in vivo (120).